# DoD Tuberous Sclerosis Complex, Clinical Translational Research Award

Source: https://welltoldgrants.com/grants/ht942524tscrpctra-dod-tuberous-sclerosis-complex-clinical-translational/  
Official notice: https://www.grants.gov/search-results-detail/353646

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $3.4 million in total. Applications closed on August 1, 2024.

| Field | Value |
|---|---|
| Opportunity number | HT942524TSCRPCTRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | August 1, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $3.4 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: · Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. · Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. · Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. · New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc. Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

## Questions people ask

### Is HT942524TSCRPCTRA still open?

No. It closed on August 1, 2024. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Tuberous Sclerosis Complex, Clinical Translational Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Tuberous Sclerosis Complex, Clinical Translational Research Award?

Closed August 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $3.4 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.